Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

SciBite launches SaaS versions of its semantic technology products

Elsevier

SciBite, an Elsevier company and award-winning semantic technology company, has today unveiled its new Software-as-a-Service (SaaS) version of TERMite, SciBite’s named entity recognition engine, and its CENtree™ ontology management platform. Researchers can use the new cloud-hosted TERMite and CENtree as part of their digital workplace, offering greater flexibility to enable them to work from multiple locations and settings. Removing the need for customers to purchase, maintain and administer both hardware and software, SaaS streamlines the deployment of SciBite tooling. Companies seeking SciBite solutions benefit from faster onboarding and avoid the infrastructure burden. Automated upgrade management guarantees that customers always benefit from the latest product version. Lee Harland, Chief Scientific Officer at SciBite, said: “The last 18 months have shown the immeasurable value that scientific research has to offer. Through global collaboration and data sharing, breakthroughs have been achieved in record time. For this speed of innovation to continue, it is crucial that the right tools and data are widely accessible. “SciBite is rapidly growing, serving customers in more regions and markets than ever before. This is the perfect time for us to take the next step and deliver our services from the cloud, widening access to more markets and to non-traditional workplaces.” SciBite uses Elsevier’s well-established cloud hosting tooling and processes, supported by a dedicated SciBite-Elsevier IT team, who proactively track and maintain this service. The SaaS offering provides continuous monitoring to ensure maximal uptime as well as following the Elsevier 10-step security policy, providing a trusted and secure environment for its hosted solutions. With the new SaaS versions of TERMite and CENtree, customers will see productivity exponentially increase through: Less procurement time, with lower overall and bundled hardware, maintenance, and administration costs. Rapid implementation of products once purchased, with seamless upgrades. Flexible access to a secure environment from multiple locations and settings. Customer-specific needs can still be addressed in consultation with SciBite’s Professional Services team. In-depth, world-class technical support is provided by SciBite’s team of subject specific and technology experts. The new SaaS version of SciBite will be available from the 30 th June. Learn more by visiting the SciBite FAQ. --- About SciBite SciBite’s data-first, semantic analytics software is for those who want to innovate and get more from their data. Leading the way by pioneering the combination of the latest in machine learning with an ontology-led approach, SciBite’s semantic infrastructure answers business critical questions in real time by releasing the value and full potential of unstructured data. Supporting the world’s leading scientific organisations with use cases from discovery through to development, SciBite’s suite of fast, flexible, deployable API technologies empower customers, making it a critical component in scientific, data-led strategies. www.scibite.com About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details SciBite Lauren Barham +44 1223 786129 lauren@scibite.com Elsevier David Tucker +447932536160 d.tucker@elsevier.com Company Website https://www.elsevier.com

June 29, 2021 04:05 AM Eastern Daylight Time

Rani Therapeutics Appoints Jean-Luc Butel and Laureen DeBuono to Board of Directors

Rani Therapeutics

Rani Therapeutics, a disrupter in oral biologics, today announced the appointment of Jean-Luc Butel and Laureen DeBuono to its Board of Directors. These new Directors bring a wide range of private and public company leadership experience at healthcare, technology and consumer companies. Jean-Luc Butel has served as a healthcare executive for more than 30 years and is a well-respected global healthcare advisor. Currently, Mr. Butel serves on various boards at Takeda, Novo Holdings, and SG Innovate, in addition to several healthcare startups in both Asia and Europe. Previously, Mr. Butel served on the board of Varian Medical Systems, the Economic Development Board (EDB) of Singapore, as a senior advisor to McKinsey’s healthcare practice and as an advisor for Singapore’s National Research Foundation. He worked in senior executive positions with Johnson & Johnson, Becton Dickinson, Medtronic and Baxter International. Mr. Butel received his B.A. from The George Washington University and an M.B.A. from the Thunderbird School of International Management. Laureen DeBuono is a seasoned executive who spent most of her career in long-term, complex Chief Operating Officer and Chief Financial Officer roles at mid and large sized healthcare and consumer-facing companies. Ms. DeBuono has also served as President, Chief Executive Officer, and General Counsel for various private and public companies across multiple sectors. Currently, she is a Managing Partner at FLG Partners, focusing on interim CEO, CFO, and Board advisory services, as well as executive coaching. Additionally, Ms. DeBuono has served on several public company Board of Directors, including Cadence Pharmaceuticals, VISX, and InVivo, and was the Audit Chair at both VISX and InVivo. Ms. DeBuono received her B.A. from Duke University, an M.A. from Stanford University, and a J.D. from New York University School of Law. “On behalf of Rani Therapeutics, I would like to welcome Jean-Luc and Laureen as members of our Board,” said Talat Imran, Rani’s Chief Executive Officer. “We look forward to benefiting from their deep and diverse executive experience.” “Rani Therapeutics has developed what I believe to be a highly differentiated biologics delivery platform that has the potential to replace subcutaneous and intravenous injections,” said Jean-Luc Butel. “I look forward to working closely with Rani’s executive leadership team and the rest of the Board as we execute on the company’s goal to deliver the RaniPill™ technology to patients worldwide.” “I am delighted to be joining Rani Therapeutics and excited by the company’s innovative RaniPill™ technology,” said Laureen DeBuono. “I hope to leverage my experience to help guide Rani through its next phases of development, including the anticipated clinical progression of its drug candidates and their potential commercialization.” About Rani Therapeutics Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to transform medicine and improve patient outcomes. The company has developed the RaniPill™ capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. Rani has conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill™ capsule. Investor Contact: investors@ranitherapeutics.com Contact Details Media Contact: media@ranitherapeutics.com

June 28, 2021 08:00 AM Pacific Daylight Time

CMS Renews Bellese Technologies Contract for Medicare Cost Estimator

Bellese Technologies, LLC

The Centers for Medicare & Medicaid Services (CMS) awarded Bellese Technologies the Medicare Cost Estimator (MCE) 2.0 contract. Bellese is the incumbent prime contractor for this project and has been awarded the MCE contract for the second time. This contract period consists of one base-period with two additional option-years. In collaboration with the CMS Office of Communications (OC), Bellese delivered CMS’s first price transparency tool, Procedure Price Lookup (PPL), in support of the 21st Century CURES ACT. “ The dedication and drive of the Office of Communication to give the best user experience to Medicare beneficiaries and their caretakers is second to none. We look forward to working by their side for another 3 years. “ said Pam Offutt, Bellese Chief Executive Officer. The products developed under the MCE contract are part of the CMS eMedicare suite of tools. The tools are designed to deliver a personalized user experience with information that empowers people to better understand cost information as it relates to care and coverage, and to use the information to get the best value when choosing healthcare providers and coverage. Bellese’s strategic focus on human-centered design practices and exploratory data analysis pinpointed multiple opportunities for price awareness by beneficiaries and caregivers. Bellese uses a hypothesis-driven rapid prototyping process and an API-first approach to develop products. In addition to the PPL tool, the MCE products include the PPL American Medical Association (AMA) API, Office Visit Pricing API, Durable Medical Equipment (DME) Supplier Directory, and an Imaging Pricing API. “ It’s exciting to see our user and data-driven design and development process at work on MCE. Extending our clinical ontology with machine learning to provide an Ontology-as-a-Service solution will improve the information we put in the hands of beneficiaries and caretakers when they need it most.” said John duClos, Bellese Chief Technology Officer. ABOUT BELLESE TECHNOLOGIES: Founded in 2009, Bellese Technologies is a human-centered service design company in the Baltimore metro area. Bellese partners with health and human services clients in the public and private sectors. The firm leverages modern technology, human-centered design, and silo-busting collaboration to help its clients expand and accelerate the positive impact they have on society. Currently, Bellese works with the Centers for Medicare & Medicaid Services, supporting price transparency, Medicare payment system modernization, and quality of care initiatives.Bellese holds the GSA IT 70 Schedule and two CMS agile blanket purchase agreements (BPA) — the Medicare Payment System Modernization (MPSM) BPA and the Agile Delivery to Execute Legislative Endeavors-Quality Related Initiatives (ADELE-QRI) BPA. Bellese was recently recognized as a “Top Workplace” by the Baltimore Sun for the third year in a row. Visit bellese.io/careers for more information on careers at Bellese. Contact Details Mark Adkins +1 202-335-0065 press@bellese.io Company Website https://bellese.io/

June 28, 2021 08:30 AM Eastern Daylight Time

Updating Video: CIPIO Appoints Serial Data & AI Entrepreneur Sundeep Sanghavi as CEO & Silicon Valley Media Tech Veteran Dipak Patel as CMO to Humanize Digital Subscriptions.

CIPIO.ai

CIPIO, an AI company that is Humanizing Subscriptions TM, today announced the appointment of Sundeep Sanghavi as its CEO and Dipak M. Patel as CMO & EVP of Strategic Initiatives. Sanghavi, a seasoned entrepreneur who has successfully founded, built, and sold four Big Data and AI companies and has invested in multiple digital oriented startups, including CIPIO. He is renowned for his obsession with data and pioneering successful AI-led business transformations across industry verticals, including global subscription and services related enterprises. Patel, prior to joining CIPIO, was most recently chartered to create and execute innovation and go-to-market models for TiVo’s IP business. And, as the Co-Founder & CEO of Zeality, Inc., Dipak built the industry’s first immersive media streaming platform. Over 25 years in Silicon Valley, Dipak has held numerous executive, go-to-market, advisory, and board positions, including G-Technology, Western Digital’s premier Media Technology storage solutions. “We’re experiencing exponential growth by onboarding great partnerships like Zype, InteliVideo, and Jonas Fitness. Globally, there are billions of subscriptions that need to be activated. To meet the demand, we’re adding powerhouse leaders like Sundeep and Dipak to our already stellar team.” said Growson Edwards, Co-Founder, and COO of CIPIO. “As experienced investors, founders, & executives, they both understand what it takes to build and scale AI, big data, and media tech companies. The CIPIO team is excited to reframe the world around Humanizing Subscriptions TM.” The global pandemic sent the world’s population into a scramble to find new ways to experience media & entertainment, teach & learn, and lead healthy lifestyles. These drivers led to a 300% growth in digital subscription activation globally. “As digital subscription growth continues to skyrocket, we believe every subscription needs a brain,” expressed Dipak M. Patel, CMO, CIPIO. “Without one, subscriptions become disposable because they’re not able to see and hear us, learn from us, and respond to our needs and feelings. We are Humanizing Subscriptions TM by giving every single subscription a brain.” By Humanizing Subscriptions TM, CIPIO empowers digital organizations to enhance the experience throughout the subscriber’s journey, including conversion from free to premium, proactively retain, and optimization of content acquisition costs. “I am obsessed with how data can truly serve humanity. Over the past year, we’ve seen a need to connect people in new ways,” said Sundeep Sanghavi, CEO, CIPIO. “As an investor and founder of multiple AI companies, CIPIO presents an opportunity to a game-changing influence on how the world interacts with their digital experiences. I’m excited to join a phenomenal team of technologists, market makers, and influencers that shares our passion for Humanizing Subscriptions TM.” About CIPIO CIPIO provides the leading patent pending AI technology platform that Humanizes Subscriptions TM for digital organizations. By bringing together human, machine, and domain data, CIPIO arms organizations with capabilities to sense, learn, predict and recommend digital experiences to strengthen the subscriber and subscription relationship. CIPIO impacts both the top and bottom line financials for some of the world’s leading brands such as Zype, InteliVideo, and Jonas Fitness. To learn more about CIPIO, visit www.cipio.ai Contact Details CIPIO Media Relations +1 925-548-7779 anita@cipio.ai Company Website https://cipio.ai/

June 24, 2021 02:55 PM Eastern Daylight Time

Video Image

With Lyme Disease on the Rise Nationwide, Quidel Corporation Urges Early Testing With Its Rapid Point-of-Care Test

Quidel Corporation

As America approaches the tail end of the COVID-19 pandemic, a quiet epidemic has emerged that has the potential to affect as many as 476,000 citizens before the year is out. The epidemic is Lyme disease, which is being identified in record numbers throughout the country.* Researchers at such institutions as Johns Hopkins, Colorado State University and SUNY Upstate Medical University in Syracuse are all reporting an increased spread of Lyme disease. And they are finding it not only in the woodlands of New England and other forested regions as typically expected but in frightening and unexpected numbers on the beaches in Northern California, throughout the southwest and southeast and other parts of the country where reported cases are on the rise. One suspected reason for the uptick is the pandemic itself, which drove people to spend more time walking outdoors and now, with restrictions being lifted, are seeing these people hitting the road for open-air destinations throughout the country. To complicate matters, this past winter was one of the warmest on record; and lingering summer heat added weeks of outdoor activity to animals that carry ticks and which thrive in hot, humid conditions. Pests.org, which produces an annual 2021 Tick Forecast, projects that “most states will experience the warmer, wetter conditions that drive tick populations—and the prospect of tick-borne diseases—skyward.” As the prevalence and fear of Lyme disease intensifies, one thing that all experts agree on is the need for testing immediately if there are signs that someone may have contracted Lyme disease. These signs may include fever, headache, fatigue, joint pain, weakness in the limbs and often a characteristic skin rash with a bull's-eye pattern. For accurate and fast testing, more and more clinicians are turning to the Sofia® 2 Lyme FIA by Quidel. This revolutionary test provides the patient and physician with indicative results within 15 minutes, as opposed to days, which has historically been the norm (and during which time organisms can spread and become systemic). It can be performed in the privacy of a doctor’s office, local clinic or even by a nurse at a children’s summer camp; and it is the only test that can get results from a simple finger prick of blood. “Not having to wait days for test results allows physicians and nurse practitioners to treat patients with positive results more rapidly while more quickly pursuing other diagnosis and treatment for those who test negative,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel Corporation. “For patients with a positive finding for Lyme, early treatment is the key; and excellent outcomes are common thanks to fabulous antibiotics now available. But if left undiagnosed or untreated, Lyme disease can lead to unintended consequences including neurological defects, heart problems (such as an irregular heartbeat), eye inflammation, liver inflammation, Bell’s palsy, meningitis and severe fatigue.” One fear that some researchers have is that some people experiencing symptoms of Lyme may have been reluctant to seek medical care over the past year, given their concerns about exposure to COVID at the doctor’s office or clinic. This could result in cases going undiagnosed and untreated, which makes Lyme disease much more serious and harder to treat later on. “As with all afflictions, the key is catching it early so effective treatment can begin as soon as possible,” said Dr. Tilghman. “Lyme disease can affect people of any age or gender. People should not hesitate to get tested, and physicians should have their radar up for signs of Lyme disease in their patients. With the general population’s increased awareness of Lyme disease, along with increased clinical awareness in the importance of early testing for tick-borne infections, later stages of Lyme disease and the life-threatening effects that accompany them should never happen.” *Sources on file at Quidel About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

June 24, 2021 01:07 PM Eastern Daylight Time

MCR Labs to Celebrate “Oil Day” with Extraction-focused Educational Virtual Event

MCR Labs

Massachusetts-based cannabis analysts MCR Labs will host a virtual event on July 8 focused on cannabis extractions and concentrated products. The event, titled “What to Expect When You’re Extracting,” will feature a panel of extraction experts discussing best practices, recent innovations, and troubleshooting tips meant to help entrepreneurs and industry colleagues refine their extraction and infusion processes. “There are a lot of variables to account for with extraction that can affect the final product,” said Kara Tracy, a lead scientist at MCR Labs. “Understanding which methods are optimal for achieving different results and knowing how to run an extraction safely is critical for anyone looking to work in an extraction lab.” Tracy will join Director of Extraction at Levia Jordani Joseph, CEO of Cannabakeri Erin Colton, Lab Director at Trade Roots Samuel Adam, and owner of Hole in The Wall Cultivation Education Mark Huard Jr. on the panel, which will be moderated by MCR Labs’ Business Development Manager Sohan Shen. The event is timed to coincide with “Oil Day” or “Dab Day,” which occurs on July 10 (7/10) and is an unofficial cannabis community holiday akin to 4/20 that is meant to celebrate concentrated cannabis products. “We’re always looking to encourage knowledge sharing and collaboration, and there’s no better time to spread some extraction advice than just before Dab Day,” said Shen who helps MCR Labs’ clients with using product testing data to improve products and processes. “What to Expect When You’re Extracting” will take place virtually on Thursday, July 8 starting at 6 p.m. Those interested to view the event live and participate in a Q&A with the panelists can register at the event homepage. A recording of the discussion and panelist responses will be posted on the MCR Labs YouTube page after the event concludes. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with multiple facilities in the Northeast region. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Joe Crinkley +1 857-230-0839 joe@mcrlabs.com Company Website http://mcrlabs.com

June 24, 2021 11:48 AM Eastern Daylight Time

Goodway Group Selected as Digital Agency of Record for Air Methods, Leading Air Medical Service Provider

Goodway Group

Goodway Group, the digital partner advertisers trust to deliver campaign performance and media efficiency, has been named the digital agency of record (DAOR) for leading air medical service provider, Air Methods Corporation. The multi-million-dollar partnership will be focused on the core services of digital media planning, execution, reporting and analytics, as well as additional services such as creative concepting and development, and enhancing dashboard analytics. Goodway Group will drive the company’s thought leadership engine by marrying their business expertise with digital strategy to create a full-funnel customer journey. As a provider responsible for delivering life-saving care to more than 70,000 people every year, Air Methods needed a digital partner who could help solve crucial challenges to deliver business outcomes in the many communities in which they operate. Goodway Group was chosen for this task largely due to their reputation for delivering strong results on multi-faceted campaigns. Throughout the partnership, Goodway Group will overcome challenges such as running ads that focus on B2C and B2B demographics and reach target audiences that change often depending on the campaign initiative. To do this, Goodway Group will focus on creating a holistic digital media strategy that utilizes all forms of media, social, SEM and display, audio, native, video, OTT and CTV. “We were thoroughly impressed with Goodway Group’s audience-first approach and how it directly aligns to our business,” said Julie Barys, Vice President of Marketing at Air Methods Corporation. “Knowing that the Goodway Group team prioritizes data first and foremost gives us confidence that they will provide full-funnel measurement across the customer journey. We couldn’t be more excited to be moving forward with them and can’t wait to see the success of our upcoming campaigns.” To continuously offer the best possible results, the Goodway Group team will be utilizing a “Test and Learn'' approach that heavily relies on data. Throughout this process, Goodway Group will also work with the Air Methods team to educate them on the value of understanding their own data to create better data segmentation for future campaigns. This will allow for audience segmentation to match their unique creative and in turn, drive better business outcomes. “From our first conversations, we knew that we had to work with the Air Methods team,” said Jed Lambert, VP Business Development and Strategy. “As one of the largest community-based providers of air medical services, the work that the company does is noble to say the least. We’re confident our data-driven approach could only help them better progress towards their mission of delivering life-saving care to communities across the country. We’re thrilled to be moving forward with this partnership and are looking forward to driving real results for their business.” About Goodway Group: Goodway Group is the digital partner advertisers trust to drive campaign performance and media efficiency. Proud to be completely independently owned and operated, Goodway provides trustworthy expertise that meets its clients' needs – and no one else's. Using predictive intelligence, Goodway helps advertisers get the most value out of every impression across all paid digital media. Through the combination of employing the smartest technology and the most experienced people in the industry, Goodway delivers authentic results. Find Goodway Group online at goodwaygroup.com. Goodway Group. Honestly Smart Digital. Contact Details Kite Hill PR for Goodway Group Bridget Callahan +1 631-338-7248 bridget@kitehillpr.com Company Website https://www.goodwaygroup.com/

June 24, 2021 10:00 AM Eastern Daylight Time

Paralyzed Veterans of America works to end handicapped parking abuse, marks 75th year advocating for accessibility

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/ulJa59_iS_w Accessible parking spaces designed specifically for people with disabilities are often misused, causing added difficulties for paralyzed veterans and others with disabilities. A survey found that 85% of Americans with disabilities struggled to find accessible parking in their communities, and over 50% turned back when they couldn’t find accessible parking. What can be done to combat this problem? Paralyzed Veterans of America (PVA) has launched the Honor the Spot campaign to encourage all Americans to do their part to keep handicapped parking spaces open for people who need them to be independent. The campaign reminds people that accessible spots are a civil right, and taking them means people with disabilities may not get to appointments and errands. The call to Honor the Spot comes as public spaces open up to larger capacities as pandemic restrictions ease, and as PVA marks its 75 th year as a voice for veterans with spinal cord conditions, and all people with disabilities. PVA is asking people to pledge to be part of the solution at pva.org/HonortheSpot, not to make excuses for taking accessible spots, and not to share handicapped placards for any reason. About Paralyzed Veterans of America: For 75 years, Paralyzed Veterans of America has been the only Veterans service organization dedicated solely to helping Veterans with spinal cord injuries and disorders (SCI/D), and diseases like MS and ALS. Our team of legislative advocates, architects, medical professionals, lawyers, and other highly trained professionals strives to ensure that every Veteran regains the freedom, independence, and quality of life they fought for. PVA is a major support system for our nation’s paralyzed heroes, their families, and caregivers, through ensuring quality health care; securing earned benefits; fighting for disability civil rights; making America more accessible; helping Veterans find meaningful careers; empowering them through sports, recreation, and wellness programs; and funding both research and education in search for a cure and improved care and autonomy for individuals with paralysis. Operating more than 70 offices in all 50 states, the District of Columbia and Puerto Rico, PVA helps paralyzed Veterans and all people with disabilities live fuller, more productive lives. Learn more at pva.org. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 23, 2021 03:00 PM Eastern Daylight Time

Video

Human and Environmental Physiology Research Unit (HEPRU) at the University of Ottawa and Innovation Canada to work with SYMP2PASS by SmartCone on COVID screening enhancements

SmartCone Technologies, Inc.

Symp2Pass by SmartCone has partnered with the HEPRU in offering the first ever personal advanced COVID screening process using ScentsiBLE a patent pending smell test process. SmartCone Technologies, Canada’s leader in IoT (Internet of Things) solutions and developer of Symp2Pass is proud to announce a strategic partnership with Innovations Canada and Dr. Glen P. Kenny, Director of the HEPRU at the University of Ottawa, Canada to further develop technologies and proprietary processes to help strengthen the return-to-work solution for COVID-19. For the past 27 years, the HEPRU has been leading innovative and cutting-edge research on the assessment of the environmental and human factors affecting health and performance ( www.hepru.ca ). This includes the development of sophisticated heat protection technologies to safeguard health and safety in partnership with SmartCone Technologies. SmartCone Technologies and its strategic partners (like Disney SyncLink) have many valuable screening, monitoring and cleaning patents and processes that will be integrated into Symp2Pass and other processes to help in the prevention and spread of COVID-19 and protect the health and wellbeing of the general population and workers Symp2Passes by SmartCone is a personal and private advanced screening process that uses a patent pending smell test (ScentsiBLE) along with a key symptom survey and required government COVID questions to quickly test individuals for key symptoms of COVID. Symp2Pass is currently being tested by Disney, Ontario Tech University (funded by the Canadian Government) and a leading nuclear power company which, will increase safety for employees, site visitors and protect the assets (buildings, complexes etc.) so that everyone carry work responsibilities and socialize safely. “We are excited to work with Symp2Pass and SmartCone to help test, verify and finalize their COVID back-to-work screening process. In combination with a COVID self- assessment questionnaire, the system offers individuals a rapid screening test that can help stop the spread of COVID and keep individuals safe and workplaces open. “ Dr. Gen P. Kenny, Director of the HEPRU uOttawa” About SYMP2PASS Powered By SmartCone SYMP2PASS, developed in conjunction with doctors and researchers, is the first anonymous end-to-end advanced health screening web process. Using our patent pending ScentsiBLE scent test paired with multi-symptom survey, SYMP2PASS will help reduce the spread of COVID and save businesses and countries millions of dollars. Learn more at www.symp2pass.com About SmartCone Technologies, Inc. SmartCone Technologies Inc. (SCTI) is a unique data sensory company that commercializes new Internet-of-Things (IoT) technologies powering a wide array of sensors, edge computing, sensor fusion and artificial intelligence (AI). TheSmartCone™ solutions have been used most recently in “ Return to Work ” solutions during the COVID-19 pandemic, as well as securing dangerous work sites, controlling bicycle lane traffic, managing vehicle fleets, smart warehouses, crowd control, and more. Visit us at www.thesmartcone.com ### For more information, please contact Richard Harris 604-808-2124 ric@symp2pass.com Contact Details Symp2Pass Richard Harris CMO +1 604-808-2124 ric@symp2pass.com Company Website https://www.thesmartcone.com

June 23, 2021 01:56 PM Eastern Daylight Time

Image

1 ... 272 273 274 275 276 ... 311